In ALK+ NSCLC Alectinib Reduces Disease Risks in Early-Stage Setting
Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.
Axi-cel Significantly Reduces Risk of Death in Patients With R/R LBCL
Treatment with axicabtagene ciloleucel in the second-line setting led to significant improvement in overall survival compared with high-dose therapy plus transplant in patients with early relapsed or refractory large B-cell lymphoma.
Dostarlimab Plus Chemotherapy Shows Similar HRQOL Results in Patients With Endometrial Cancer
New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.
STRIDE Regimen Exhibits Manageable Safety in Patients With uHCC
According to George Lau, MD, FRCP, FAASLD, patients with unresectable hepatocellular carcinoma who experienced immune-related adverse events with the STRIDE regimen were not precluded from receiving survival benefit.
Study Shows Feasibility of Using Exome Sequencing to Conduct CDCT1 Genetic Condition Screening
Whole-exome sequencing demonstrated the ability to identify genetic conditions in patients for whom clinical guidelines did not require testing.
Carolina Frailty Index Score Validated in Ovarian Cancer
Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.
GCLQ and LELSQ Shows Similar Total Scores in Assessment of Lymphedema in Endometrial Cancer
A correlation in total scores were seen between the gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire, according to findings presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma
Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.
Gastric and Breast Cancer HER2 Testing Practices Show Potential in mCRC
Breast and gastric cancer algorithms are acceptable to use when identifying patients with colorectal cancer who may respond to tucatinib in combination with trastuzumab.
Addition of Pembrolizumab to Lenvatinib for HCC Elicits Similar Scores in LEAP-002
Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.
PROs Data Support Use of Upfront Daratumumab Quadruplet for Transplant Eligible, Newly-Diagnosed MM
Encouraging health-related quality of life benefit was demonstrated in for patients with transplant eligible, newly diagnosed multiple myeloma treated with a daratumumab quadruplet regimen.
Neoadjuvant Trastuzumab Deruxtecan +/- ET Shows Encouraging Responses in Operable HR+, HER2-Low Breast Cancer
The use of trastuzumab deruxtecan in the neoadjuvant setting showed promising responses in patients with early-stage breast cancer.
KEYNOTE-522 Trial of Pembrolizumab Does Not Negatively Affect HRQOL Outcomes in TNBC
Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.
Trastuzumab Deruxtecan Preserves QOL in HER2-Low Breast Cancer
Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.
Autologous T-Cell Therapy Shows Antitumor Responses Across MAGE-A4+ Unresectable or Metastatic Tumor Types
ADP-A2M4CD8, an autologous T-cell therapy, showed promising antitumor activity in several solid tumor types including ovarian, gastric, and urothelial cancer.
Consistent Survival Outcomes With Ribociclib Dose Reductions in HR+/HER2- Advanced Breast Cancer
Patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib had comparable overall survival outcomes to those given the standard dose.
Avasopasem Treatment Lead to Fewer Severe Oral Mucositis in Patients Receiving Chemoradiotherapy for Advanced Head and Neck Cancer
Reductions in severe oral mucositis across all intensity-modulated radiotherapy landmarks was observed with avasopasem treatment in patients with locally advanced, nonmetastatic head and neck cancer.
Investigators Hope Oregovomab Combo Will Show Benefit in Advanced Epithelial Ovarian Cancer
A new murine monoclonal antibody B43.12 is under investigation in combination with paclitaxel and carboplatin as a treatment option for patients with advanced epithelial ovarian cancer.
Benefit of Co-Treatment Chemotherapy and Vitamin C in Cisplatin-Ineligible MIBC
Chemotherapy plus intravenous vitamin C shows benefit in cisplatin-ineligible patients with locally advanced muscle-invasive bladder cancer.
Association Between irAEs and Prolonged Survival With Pembrolizumab in Metastatic Urothelial Carcinoma
Immune-related adverse effects may show significantly longer progression-free survival and overall survival in patients with metastatic urothelial carcinoma who are receiving pembrolizumab.
Belimumab May Be a Prophylaxis Option for cGVHD After Allogenic Transplant
The majority of patients treated in a phase 1 trial of belimumab used as chronic graft-vs-host-disease prophylaxis showed no evidence of the disease after 20 months of follow-up.
Two Subtypes Linked to Improved Response to Durvalumab Plus Chemotherapy in ES-SCLC
Nivolumab/Cabozantinib Shows More Sustainable Health-Related QOL in Frontline RCC
Health-related quality of life outcomes was more sustainable in patients with advanced renal cell carcinoma on nivolumab plus cabozantinib compared to sunitinib.
Urine Cytology NGS Comparable to Tumor Biopsy in Identifying UTUC Mutations
Next-generation sequencing samples of urine cytology specimens from upper tract urothelial carcinoma demonstrated an 86% success rate.
Pembrolizumab Plus Chemotherapy Represents New SOC for Esophageal Cancer/ GEJ Adenocarcinoma
According to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit.
Certain Pathways in Gut Microbiome May Predict IRAEs With Nivolumab in Advanced Gastric Cancer
Single nucleotide polymorphisms such as NOTCH1, SEMA4D, NLRC5, and IL6R, may be predictive of nivolumab toxicity in advanced gastric cancer.
Amphiregulin May Be Useful for Longitudinal Monitoring in aGVHD That is Life Threatening
Patients with high levels of amphiregulin appeared to be at a higher risk of early death from acute graft-versus-host-disease, signaling that it may be a predictive biomarker.
WBC Potentially Linked to Thrombosis in Polycythemia Vera
Results from the REVEAL study signal link between thrombotic events and white blood cell counts.
Efficacy in Relapsed/Refractory Multiple Myeloma With t(11;14) Seen With Venetoclax/Selinexor Combo
In patients with relapsed/refractory multiple myeloma with t(11;14), Selinexor plus venetoclax induced decreases in cyclin D1, XPO1, and MCL-1.
Pirtobrutinib Treatment in MCL Models Overcome Resistant to Ibrutinib/Venetoclax
The novel non-covalent BTK inhibitor pirtobrutinib has shown encouraging preclinical efficacy in addressing resistance to ibrutinib and venetoclax resistance in mantle cell lymphoma models cell lines.
2 Clarke Drive Cranbury, NJ 08512